Navigation Links
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Date:5/30/2008

tients will present with or eventually develop metastatic, incurable disease.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the pub
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... 26, 2014 The report "Data ... Network Security Equipment, WAN Optimization Appliances]: Global Advancements, ... the data center networking market into various segments ... The report also identifies the factors driving this ... it along with the future roadmaps. , Browse ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... New York, NY (PRWEB) October 23, 2014 ... today announced the winners for the 2014 BioProcess ... collaborations, business strategies, social corporate responsibility and technology ... better, more effective treatments to a global patient ... recognized by their peers during a very entertaining ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 DuPont ... plans to more than double the acreage contracted ... geographies supplying its soybean crush facility in Salisbury, ... this program will target several markets including foodservice ... with good performance. , For the 2015 growing ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... amounts are in U.S. dollars, QUEBEC CITY, May ... TSX: AEZ), a global biopharmaceutical company focused on,endocrinology and ... quarter ended March 31, 2008., First Quarter ... second efficacy trial of the Phase ...
... Calif., May 6 Finesse Solutions, LLC,Santa ... control solutions for,life sciences process applications, announced ... of Software. Basil brings over 19 years ... a focus on,implementing high efficiency engineering, resource ...
... Genta,Incorporated (OTC Bulletin Board: GNTA) announced today ... Regulatory Authority (FINRA, formerly,the NASD) has cleared a ... stock on the Over-the-Counter Bulletin Board (OTCBB). As ... for the Company,s,common stock will begin on Wednesday, ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7Basil Zimmo Joins Finesse Solutions as Vice-President of Software 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3
(Date:10/29/2014)... a large cohort of kidney cancer patients in Europe ... -- and reveals an apparent link between exposure to ... Romania. , The research, by an international team led ... Innovation Centre in Montreal, underscores the importance of investigating ... found in plants of the Aristolochia genus, also has ...
(Date:10/28/2014)... (NIH) announced awards to expand the Office of ... for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases ... physician scientists at 22 consortia will work with ... and investigate new treatments for patients with rare ... million in fiscal 2014 funding from NIH. , ...
(Date:10/28/2014)... and juices are associated with a lower risk of ... University of East Anglia (UEA). , Research published ... and flavanones (both subclasses of dietary flavonoids) significantly decrease ... cause of cancer death among women. , The ... aged between 25 and 55 for more than three ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... WASHINGTON Synthetic biology promises to enable cheap, lifesaving ... suffer from malaria, and to create innovative biofuels that ... the science and its applications are raising questions: ... purposely changing the definition of what is life? ...
... Carolina, there are five strange looking "patches" cleared out ... circles carved by aliens. , They,re actually budding longleaf ... St. Louis and their collaborators at North Carolina State ... Washington have created these ecological patches with the help ...
... French . Plant researchers from ... announced a major breakthrough in a developmental process called ... reversal of what is called epigenetic silencing in plants. ... better understanding of gene regulation in the continuing quest ...
Cached Biology News:Synthetic biology: Is ethics a showstopper? 2Study on wildlife corridors shows how they work over time 2Study on wildlife corridors shows how they work over time 3Study on wildlife corridors shows how they work over time 4Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: